Lenalidomide Mylan (Lenalidomide)

Lenalidomide is an immunomodulatory agent used in the management of hematologic cancers, targeting malignant plasma cells and related pathways.

• Multiple myeloma: Reduces disease progression, prolongs progression‑free survival, and improves overall survival when used in combination with dexamethasone in adult patients.
• Myelodysplastic syndromes: Enhances hematologic response, increases platelet and neutrophil counts, and lowers the likelihood of progression to acute myeloid leukemia in eligible patients.
• Mantle cell lymphoma: Offers therapeutic benefit in relapsed or refractory disease, contributing to tumor size reduction and extended duration of response.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in reduced proliferation of malignant plasma cells, enhanced immune‑mediated tumor cell killing, and inhibition of angiogenesis. Additionally, lenalidomide modulates cytokine production, increasing interleukin‑2 and interferon‑γ while decreasing tumor necrosis factor‑α, further contributing to its antitumor activity.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: Persistent tiredness or lack of energy.
• Nausea: Feeling of sickness, sometimes with vomiting.
• Diarrhea: Loose or watery stools.
• Rash: Skin redness or irritation.
• Constipation: Difficulty passing stools.
• Muscle cramps: Involuntary tightening of muscles.

Serious or Rare Side Effects

• Thromboembolic events: Deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: Markedly low neutrophil count increasing infection risk.
• Severe thrombocytopenia: Critically low platelet count leading to bleeding.
• Secondary primary malignancies: Development of new cancers unrelated to original disease.
• Hepatotoxicity: Significant liver enzyme elevation or liver injury.

Before prescribing lenalidomide, clinicians should consider several safety precautions to minimize risks.

• Pregnancy risk: Contraindicated in pregnancy (Category X); ensure effective contraception for both male and female patients.
• Thromboembolic prophylaxis: Assess need for anticoagulation in patients with additional risk factors.
• Renal function: Adjust monitoring in patients with impaired kidney function.
• Hematologic monitoring: Perform regular complete blood counts to detect neutropenia or thrombocytopenia.
• Infection vigilance: Monitor for signs of infection and manage promptly.
• Store at ambient temperature: Keep tablets in original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: May reduce lenalidomide exposure.
• Anticoagulants (warfarin, DOACs): Increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia.
• Live vaccines: Immunosuppression may diminish vaccine effectiveness and increase infection risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors: Potentially increase lenalidomide levels.
• Immunosuppressants (e.g., cyclosporine): May enhance immunomodulatory effects.
• Hormonal contraceptives: Possible reduced efficacy; advise additional contraceptive methods.